Market reactionShares fell 11% on Nov 5.
Autolus Therapeutics is a commercial-stage cell therapy company whose approved lead product treats relapsed or refractory B-cell acute lymphoblastic leukemia in adults, and whose pipeline includes an unapproved cell therapy for lupus nephritis.
AUCATZYL, approved for adults with relapsed or refractory B-cell ALL, is growing: net revenue was $26.2M in Q1 and $45.7M in Q2 2026, with gross margin rising from 6% to 55%. Autolus guides funding into Q2 2028, assuming expected AUCATZYL revenue and the first $100M of a credit facility, $75M of it drawn. The larger opportunity is lupus: LUMINA data in lupus nephritis are expected in 2028.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Longer follow-up supports the SLE signal
Does longer follow-up show the benefit in severe refractory lupus lasts?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
AUCATZYL sales are growing as Autolus pursues lupus expansion; LUMINA data will test the larger opportunity
AUCATZYL commercial inflection funding an autoimmune platform expansion — whether obe-cel's CD19 CAR-T durability translates beyond ALL determines the multiple
AUCATZYL's commercial ramp and autoimmune pipeline expansion hinge on whether revenue growth can fund operations through key registrational readouts
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Drug pages: Obecabtagene autoleucel (obe-cel)
Disease areas: Blood cancers, Kidney diseases, Neurology and pain, Blood disorders, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
11 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.